Antihypertensive Therapies and Cognitive Function: a Review

  • Nisharahmed Kherada
  • Todd Heimowitz
  • Clive Rosendorff
Hypertension and the Brain (S Stocker, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hypertension and the Brain

Abstract

Increasing life expectancy has made old age-related health problems like dementia and cognitive decline more prevalent, and these are rapidly becoming important causes of disability and poor quality of life, causing significant add-ons to health-care costs worldwide. Hypertension is the most important modifiable vascular risk factor for the development and progression of both cognitive decline and dementia. In many observational and randomized studies, antihypertensive therapies have been shown to be beneficial in slowing cognitive decline. However, due to observed discrepancies by these studies, there is a lack of consensus on the best antihypertensive strategy for the prevention or slowing of cognitive decline. It is also not clear whether the beneficial effect of antihypertensive therapy is due to the use of a specific class of agents or combination therapy. Thus, we present a comprehensive review of overall antihypertensive therapies and cognition and of the individual antihypertensive therapy classes with their specific protective mechanisms and available clinical evidence behind their effect on cognitive function.

Keywords

Dementia Cognition Alzheimer’s disease Stroke Antihypertensive therapies 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Kherada, Dr. Heimowitz, and Dr. Rosendorff declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer’s disease. Am J Geriatr Cardiol. 2007;16(3):143–9.CrossRefPubMedGoogle Scholar
  2. 2.•
    Gasecki D et al. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547–58. A review discussing the link between HTN brain functional and structural changes, and to cognitive decline and dementia and the role of antihypertensive therapies in prevention of cognitive decline.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Wimo A et al. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11. e3.CrossRefPubMedGoogle Scholar
  4. 4.
    Frishman WH. Are antihypertensive agents protective against dementia? a review of clinical and preclinical data. Heart Dis. 2002;4(6):380–6.CrossRefPubMedGoogle Scholar
  5. 5.
    MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Gorelick PB et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012;6(5):309–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Alrawi YA et al. Pharmacological blood pressure lowering in the older hypertensive patients may lead to cognitive impairment by altering neurovascular coupling. Med Hypotheses. 2013;80(3):303–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hajjar I et al. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension. 2010;56(5):859–64.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Hajjar I et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the cardiovascular health study. Circulation. 2011;123(8):858–65.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Hofman A et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349(9046):151–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Appelman AP et al. White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. Cerebrovasc Dis. 2010;29(1):28–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Waldstein SR et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51(1):99–104.CrossRefPubMedGoogle Scholar
  14. 14.
    Nation DA et al. Elevated pulse pressure is associated with age-related decline in language ability. J Int Neuropsychol Soc. 2010;16(5):933–8.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Gustafson DR et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging. 2010;31(6):910–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension. 2008;52(1):37–43.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.•
    Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer’s disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30 Suppl 2:S251–68. A recent article reviews current evidence on effect of ACE-inhibitors and ARBs in treatment of AD.PubMedGoogle Scholar
  18. 18.
    Elias MF et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353–64.PubMedGoogle Scholar
  19. 19.
    Whitmer RA et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Launer LJ et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Launer LJ et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Yamada M et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51(3):410–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Skoog I et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Kilander L et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31(3):780–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Mahoney JR et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc. 2010;16(5):877–89.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Nilsson SE et al. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75.CrossRefPubMedGoogle Scholar
  28. 28.
    Obisesan TO. Hypertension and cognitive function. Clin Geriatr Med. 2009;25(2):259–88.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Forette F et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.CrossRefPubMedGoogle Scholar
  30. 30.
    No authors listed. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24)3255–64.Google Scholar
  31. 31.
    Lithell H et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Peters R et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Prince MJ et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ. 1996;312(7034):801–5.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Anderson C et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43–53.CrossRefPubMedGoogle Scholar
  35. 35.
    McGuinness B et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;2:CD004034.PubMedGoogle Scholar
  36. 36.
    Inaba S et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke. 2009;40(2):597–603.CrossRefPubMedGoogle Scholar
  37. 37.
    Inaba S et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009;53(2):356–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Yagi S et al. Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertens Res. 2013;36(9):753–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Pihlaja R et al. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia. 2011;59(11):1643–57.CrossRefPubMedGoogle Scholar
  40. 40.
    Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol. 2007;6(4):373–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med. 2008;86(6):715–22.CrossRefPubMedGoogle Scholar
  42. 42.
    Ciobica A et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109(3):171–80.PubMedGoogle Scholar
  43. 43.
    Savaskan E et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging. 2001;22(4):541–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc. 1996;44(4):411–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Ohrui T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich). 2007;9(6):454–9.CrossRefGoogle Scholar
  47. 47.
    Fournier A et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413–31.CrossRefPubMedGoogle Scholar
  48. 48.
    Fogari R et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59(12):863–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Fogari R et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177–85.CrossRefPubMedGoogle Scholar
  50. 50.
    Li NC et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.•
    Levi Marpillat N et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82. A network meta-analysis showing class difference of antihypertensive therapies on beneficial effects on cognitive decline and prevention of dementia, with ARBs possibly being the most effective.CrossRefPubMedGoogle Scholar
  52. 52.
    Ito S et al. Renin-angiotensin system in the brain as a new target of antihypertensive therapy. Hypertens Res. 2008;31(8):1487–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Takeda R et al. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18(5):370–3.CrossRefGoogle Scholar
  54. 54.
    Yagi S et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res. 2011;34(1):74–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Khachaturian AS et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686–92.CrossRefPubMedGoogle Scholar
  56. 56.
    Yasar S et al. Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study. Alzheimers Dement. 2012;8(3):188–95.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci. 2004;1019:19–23.CrossRefPubMedGoogle Scholar
  58. 58.
    Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008;29(2):306–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Sze KH et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand. 1998;97(6):386–92.CrossRefPubMedGoogle Scholar
  60. 60.
    Pantoni L et al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175(2):116–23.CrossRefPubMedGoogle Scholar
  61. 61.
    Arrieta-Cruz I et al. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;21(2):649–54.PubMedGoogle Scholar
  62. 62.
    Wang J et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging. 2011;32(12):2321. e1-12.PubMedCentralCrossRefPubMedGoogle Scholar
  63. 63.
    Dobarro M et al. Propranolol restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013;64:137–44.CrossRefPubMedGoogle Scholar
  64. 64.
    Madden DJ, Blumenthal JA, Ekelund LG. Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. Hypertension. 1988;11(5):470–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Fogari R et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17(11):781–5.CrossRefPubMedGoogle Scholar
  66. 66.•
    Yasar S et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896–903. A recent study showing antihypertensive therapies reducing risk of AD dementia independent of mean systolic blood pressure.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.•
    Gelber RP et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888–95. A recent community-based study showing beneficial effect of beta-blockers in prevention of cognitive decline in elderly >75 years.PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Di Bari M et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol. 2001;153(1):72–8.CrossRefPubMedGoogle Scholar
  69. 69.•
    Douiri A et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013;128(12):1341–8. A recent large community based study indicating post stroke preventive antihypertensive therapy and long-term reduced risk of cognitive impairment.CrossRefPubMedGoogle Scholar
  70. 70.•
    Ambrosius WT et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–46. An ongoing RCT evaluating impact of optimal blood pressure control (120 versus 140 mmHg systolic) on multiple clinical endpoints including cognitive function.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Nisharahmed Kherada
    • 1
  • Todd Heimowitz
    • 1
  • Clive Rosendorff
    • 2
  1. 1.Department of Cardiology, Mount Sinai Medical CenterColumbia UniversityMiami BeachUSA
  2. 2.Department of Cardiology, James J. Peters VA Medical CenterIcahn School of Medicine at Mount SinaiBronxUSA

Personalised recommendations